Nektar Therapeutics (India) Private Limited

Nektar Therapeutics (India) Private Limited - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN U24239TG2005FTC046253 Incorporated 16 May 2005 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Foreign Private Limited Company pharma
Revenue · FY 2025
₹3.39 Cr
▼ 8% YoY
Net profit · FY 2025
₹1.77 Cr
Net margin 52.1%
EBITDA · FY 2025
₹2.53 Cr
EBITDA margin 74.7%
Authorised capital
₹30 Cr
Registered with MCA
Paid-up capital
₹29.39 Cr
Issued & subscribed
Company age
21 yrs
Est. 2005
Employees · EPFO
3
Provident fund records
Directors on board
3
As per MCA filings

About Nektar Therapeutics (India) Private Limited

Data last updated:

Nektar Therapeutics (India) Private Limited is a foreign private limited company based in Hyderabad, Telangana, India, a subsidiary of Nektar Therapeutics, Usa. It operates in the pharma contract r and d segment of the pharmaceuticals sector. It was incorporated on 16 May 2005 and has been in existence for over 21 years.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN U24239TG2005FTC046253. The company has 3 GST registrations on record, none of which is active.

The company has an authorised share capital of ₹30 Cr and a paid-up capital of ₹29.39 Cr. It is led by directors including Mark Andrew Wilson and Uday Chandra Yemmanuru.

Its last annual general meeting (AGM) was held on 30 September 2024, and its latest financial statements are for the year ended 31 March 2024. The registered office is at Hyderabad, Telangana.

As per the financials filed for FY 2025, the company reported a revenue of ₹3.39 Cr, a decline of 8% compared to the previous year. For the same year it recorded a net profit of ₹1.77 Cr (net margin 52.1%) and EBITDA of ₹2.53 Cr (EBITDA margin 74.7%). Revenue has declined at a compounded annual rate (CAGR) of 65% over three years and 46% over five years.

The company has about 3 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Nektar. Court records list 6 cases involving the company, including 5 filed by the company and 1 filed against it; 1 case is pending. The company has 3 deals on record (2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹29.38 Cr; the latest was in April 2009. Its 5 peer companies in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development) are compared by revenue, 1 larger and 4 smaller; the largest is Almora Botanica India Private Limited with revenue of ₹3.4 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website nektar.com.

Company details

CIN U24239TG2005FTC046253
Registration Number 046253
Incorporation Date 16 May 2005
ROC Hyderabad
Listing Status Unlisted
Company Status Active
Parent Company Nektar Therapeutics, Usa
Compliance Status Active Compliant

CIN history

Nektar Therapeutics (India) has one previous CIN (Corporate Identification Number): U24239AP2005FTC046253. The current CIN is U24239TG2005FTC046253, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
U24239TG2005FTC046253Current
U24239AP2005FTC046253Previous

Contact details

Nektar Therapeutics (India) Private Limited's registered office is in Hyderabad, Telangana. Its website is nektar.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
  • Social Media
  • Registered Address
    Plot No. 105/1 P&T Colony, Tirumalgherry, Hyderabad, Telangana, India – 500015
  • Industry
    Pharma, Pharma Contract R&D

To see the full contact details of Nektar Therapeutics (India) Private Limited, buy the company report.

Comprehensive company report
Nektar Therapeutics (India) Private Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Nektar Therapeutics (India) operates one associated brand: Nektar. Each brand links to its own profile.

BrandDescriptionWebsite
Therapeutics for multiple diseases are developed using PEGylation platforms.nektar.com

Financials of Nektar Therapeutics (India) Private Limited

FY 2024 filings available

Nektar Therapeutics (India) Private Limited reported revenue of ₹3.39 Cr (down 8% YoY) for FY 2025.

Revenue · FY 2025
₹3.39 Cr ▼ 8%
Net profit · FY 2025
₹1.77 Cr margin 52.1%
EBITDA · FY 2025
₹2.53 Cr margin 74.7%

Compounded Annual Growth Rate (CAGR)

Revenue CAGR growth
1 year
▼ 8%
3 years · compounded
▼ 65%
5 years · compounded
▼ 46%
EBITDA CAGR growth
1 year
▲ 179%
3 years · compounded
▲ 80%
5 years · compounded
▼ 34%

Revenue has declined at a compounded annual rate (CAGR) of 46% over five years, including a 8% fall in the latest year. EBITDA rose 179% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.

Financial Statement Summary

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profit and Loss Statement
Revenue from Operations
Other Income
Total Revenue
Cost of Materials Consumed
Employee Benefit Expense
Finance Costs
Depreciation and Amortisation
Other Expenses
Total Expenses
EBITDA₹2.53 Cr
Profit Before Tax
Tax Expense
Net Profit (PAT)₹1.77 Cr
Balance Sheet
Share Capital
Reserves and Surplus
Net Worth (Total Equity)
Long-term Borrowings
Short-term Borrowings
Trade Payables
Total Liabilities
Fixed Assets
Investments
Inventories
Trade Receivables
Cash and Bank Balance
Total Assets

Financial Ratios

MetricsFY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Profitability
EBITDA Margin74.7%
Net Profit Margin52.1%
Return on Equity (ROE)
Return on Capital Employed (ROCE)
Return on Assets (ROA)
Liquidity and Debt
Current Ratio
Quick Ratio
Debt-to-Equity Ratio
Interest Coverage Ratio
Efficiency and Growth
Asset Turnover
Receivable Days
Payable Days
Inventory Days
Revenue Growth
Net Profit Growth

To see the full financial statements and ratios of Nektar Therapeutics (India) Private Limited, buy the company report.

Board of directors of Nektar Therapeutics (India) Private Limited

Nektar Therapeutics (India) has 3 current directors and 20 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Mark Andrew WilsonDirector19 Mar 20197 Years 8 MonthsCurrent
Uday Chandra YemmanuruDirector25 Mar 20242 Years 7 MonthsCurrent
Robert Michael BacciDirector18 Jun 20242 Years 5 MonthsCurrent

Peer comparison

Nektar Therapeutics (India) Private Limited is compared with the 5 companies closest to it by revenue in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Almora Botanica India Private Limited₹3.4 Cr (FY 2025)-38.0%Bangalore, Karnataka, India
Nektar Therapeutics (India) Private Limitedthis company₹3.39 Cr (FY 2025)₹1.77 Cr52.1%-8.0%3Hyderabad, Telangana, India
Vyome Therapeutics Limited₹3.35 Cr (FY 2025)-12.0%Vadodara, Gujarat, India
Par Biosciences Private Limited₹3.31 Cr (FY 2025)1.0%Chennai, Tamil Nadu, India
GMK Research Laboratories Private Limited₹3.27 Cr (FY 2025)-20.0%Secunderabad, Telangana, India
Mediception Science Private Limited₹3.27 Cr (FY 2024)35.0%Gurgaon, Haryana, India

To see the full peer comparison of Nektar Therapeutics (India) Private Limited, buy the company report.

Auditor

Nektar Therapeutics (India) Private Limited is audited by S. R. BATLIBOI & ASSOCIATES for the financial year 2023.

Auditor firmFinancial yearFirm registration number
S. R. BATLIBOI & ASSOCIATESFY 2023101049W

Shareholding

The shareholding of Nektar Therapeutics (India) Private Limited is on record for 5 financial years, the latest being FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.

Shareholder categoryFY 2023FY 2021FY 2020FY 2019FY 2018
Promoters
Domestic institutional investors (DII)
Foreign institutional investors (FII)
Public
Others

To see the full shareholding pattern of Nektar Therapeutics (India) Private Limited, buy the company report.

Deals & funding

Nektar Therapeutics (India) Private Limited has 3 deals on record (2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹29.38 Cr; the latest was in April 2009.

Total deals
3
Funding rounds
2
Secondary share transfer
1
Disclosed funding
₹29.38 Cr

Deals on record (3 of 3)

WhenDealAmountParties
Apr 2009Funding round₹15.69 CrInvestors: an individual
Feb 2007Funding round₹13.69 CrInvestors: an individual
Jul 2006Secondary share transferUndisclosedBuyer: 2 individuals
Seller: 2 individuals

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Nektar Therapeutics (India) Private Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Nektar Therapeutics (India) Private Limited has a workforce of 3 employees on its EPFO records as of Mar 2024, across 1 active EPFO establishment.

Employee count
3
Active EPFO establishments
1

Headcount by financial year

Financial yearEmployees (EPFO)
FY 2023-243
FY 2022-23
FY 2021-22
FY 2020-21
FY 2019-20
FY 2018-19
FY 2017-18
FY 2016-17

To see the full employee and EPFO history of Nektar Therapeutics (India) Private Limited, buy the company report.

GST

Nektar Therapeutics (India) has 3 GST registrations on record, and all of them have been cancelled or are inactive. Only active GST numbers are listed on this page.

Total GSTINs
3
Cancelled / inactive
3

To see the full GST registrations and return filing status of Nektar Therapeutics (India) Private Limited, buy the company report.

Recent activity

Nektar Therapeutics (India) Private Limited has 22 board changes on record since 2007: 3 appointments and 19 cessations. The latest: Robert Michael Bacci ceased to be Additional Director on 29 Sep 2024.

AGM
Nektar Therapeutics (India) Private Limited last Annual general meeting of members was held on 30 Sep 2024 as per latest MCA records.
Ceased
Robert Michael Bacci ceased to be Additional Director.
Ceased
Uday Chandra Yemmanuru ceased to be Additional Director.
Appointed
Robert Michael Bacci was appointed as Director.
Filing
Nektar Therapeutics (India) Private Limited has filed its annual Financial statements for the year ended 31 Mar 2024 with Roc Hyderabad.
Appointed
Uday Chandra Yemmanuru was appointed as Director.
Ceased
Jonathan Zalevsky ceased to be Director.
Ceased
Kevin John Brodbeck ceased to be Director.
Ceased
Mark Andrew Wilson ceased to be Director.
Ceased
Maninder Singh Hora ceased to be Director.
Ceased
Gilbert Mercier Labrucherie Jr ceased to be Director.
Appointed
Mark Andrew Wilson was appointed as Director.

13 earlier events are in the company report.

Frequently asked questions

Nektar Therapeutics (India) is an active foreign private limited company based in Hyderabad, Telangana, India. The company works in pharma contract r and d, within the pharma industry. It was incorporated on 16 May 2005 (21+ years old) and is registered under CIN U24239TG2005FTC046253.

Nektar Therapeutics (India) has 3 current directors:

The latest financial statements of Nektar Therapeutics (India) on record with the MCA are for the year ended 31 March 2024. Its last annual general meeting was held on 30 September 2024. Year-wise statements from 2015 are in the company report.

No. Nektar Therapeutics (India) has 3 GST registrations on record and all of them are cancelled or inactive.

The CIN (Corporate Identification Number) of Nektar Therapeutics (India) is U24239TG2005FTC046253. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Nektar Therapeutics (India) has 6 court cases on record: 5 filed by the company and 1 filed against it. 1 is pending. Most are in the high courts.

Nektar Therapeutics (India) was incorporated on 16 May 2005, making it 21+ years old. It is registered with the Registrar of Companies, Hyderabad.

Nektar Therapeutics (India) has 3 deals on record (2 funding rounds, 1 secondary share transfer), with disclosed funding of ₹29.38 Cr; the latest was in April 2009.

The peers of Nektar Therapeutics (India) by revenue are Almora Botanica India Private Limited, Vyome Therapeutics Limited, Par Biosciences Private Limited, GMK Research Laboratories Private Limited, Mediception Science Private Limited, all in the Pharma industry (Contract Research), with the same principal business activity (scientific research and development).

Robert Michael Bacci ceased to be Additional Director on 29 Sep 2024. Uday Chandra Yemmanuru ceased to be Additional Director on 29 Sep 2024. Robert Michael Bacci was appointed as Director on 18 Jun 2024. Nektar Therapeutics (India) has 22 board changes on record in total.

Nektar Therapeutics (India) can be reached through the website nektar.com. Its registered office is in Hyderabad, Telangana, India.